Related Experiment Videos
C3 polymorphism and circulating immune complexes in patients with multiple sclerosis
Insights
The C3F gene variant is more common in multiple sclerosis (MS) patients with circulating immune complexes (CIC), suggesting a genetic predisposition to MS. Low C3 levels were observed in MS patients without CIC.
Area of Science:
- Immunology
- Genetics
- Neurology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- The complement system, particularly complement factor C3, plays a role in immune responses.
- Circulating immune complexes (CIC) are implicated in various autoimmune conditions.
Purpose of the Study:
- To investigate the association between complement factor C3 phenotypes and the presence of CIC in multiple sclerosis (MS) patients.
- To explore the potential genetic predisposition to MS related to C3 gene variants.
Main Methods:
- Evaluation of complement factor C3 phenotypes in 60 MS patients.
- Correlation of C3 phenotypes with the occurrence of circulating immune complexes (CIC).
- Analysis of C3 serum levels and C3-type distribution.
Main Results:
- A significantly increased frequency of the C3F gene was observed in MS patients, strongly associated with CIC.
- C3F-positive individuals among MS patients with CIC had a relative risk incidence of 4.1.
- Low C3 serum levels were found in 30% of patients, primarily those without CIC and exhibiting a normal C3-type distribution.
Conclusions:
- The C3F gene variant is associated with CIC in MS patients, suggesting a genetically determined immunological abnormality that may predispose individuals to MS.
- A type II immunological reaction pattern may be involved in MS patients with low C3 levels and without CIC.
Abstract:
The phenotypes of the complement factor C3 have been evaluated in 60 patients with multiple sclerosis (M.S.), and the results correlated to the occurrence of circulating immune complexes (CIC). A significantly increased frequency of the C3F-gene was found among the patients, and closely associated with the occurrence of CIC. A relative risk incidence of 4.1 was found for C3F-positive individuals among M.S. patients with detectable CIC. Low C3 levels in serum were found in 30% of the patients, almost all belonged to the group without CIC and showed a C3-type distribution similar to normal controls. A different immunological reaction pattern (type II reaction) in these patients seems possible, and a genetically determined immunological abnormality predisposing to M.S. is therefore suggested.